HK1149279A1 - Use of peptides derived from copolymer-1 as molecular weight markers - Google Patents

Use of peptides derived from copolymer-1 as molecular weight markers

Info

Publication number
HK1149279A1
HK1149279A1 HK11103596.9A HK11103596A HK1149279A1 HK 1149279 A1 HK1149279 A1 HK 1149279A1 HK 11103596 A HK11103596 A HK 11103596A HK 1149279 A1 HK1149279 A1 HK 1149279A1
Authority
HK
Hong Kong
Prior art keywords
molecular weight
weight markers
copolymer
copolymers
glatiramer acetate
Prior art date
Application number
HK11103596.9A
Other languages
English (en)
Inventor
Alexander Gad
Dora Lis
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22285926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1149279(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of HK1149279A1 publication Critical patent/HK1149279A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
HK11103596.9A 1998-09-25 2011-04-08 Use of peptides derived from copolymer-1 as molecular weight markers HK1149279A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10169398P 1998-09-25 1998-09-25

Publications (1)

Publication Number Publication Date
HK1149279A1 true HK1149279A1 (en) 2011-09-30

Family

ID=22285926

Family Applications (3)

Application Number Title Priority Date Filing Date
HK02100390.4A HK1040521A1 (en) 1998-09-25 2002-01-18 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
HK09111514.5A HK1133021A1 (en) 1998-09-25 2009-12-09 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
HK11103596.9A HK1149279A1 (en) 1998-09-25 2011-04-08 Use of peptides derived from copolymer-1 as molecular weight markers

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK02100390.4A HK1040521A1 (en) 1998-09-25 2002-01-18 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
HK09111514.5A HK1133021A1 (en) 1998-09-25 2009-12-09 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use

Country Status (18)

Country Link
EP (3) EP2239269B1 (xx)
JP (2) JP4629229B2 (xx)
AT (2) ATE516297T1 (xx)
AU (1) AU757413B2 (xx)
CA (2) CA2794705C (xx)
CY (3) CY1110490T1 (xx)
DE (2) DE09004306T1 (xx)
DK (3) DK1115743T3 (xx)
ES (3) ES2369642T3 (xx)
HK (3) HK1040521A1 (xx)
HU (3) HU229289B1 (xx)
IL (4) IL142116A0 (xx)
NO (2) NO329877B1 (xx)
NZ (1) NZ511020A (xx)
PT (3) PT2239269E (xx)
SI (1) SI1115743T1 (xx)
WO (1) WO2000018794A1 (xx)
ZA (1) ZA200102269B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
WO2001097785A2 (en) * 2000-06-20 2001-12-27 Caprion Pharmaceuticals Inc. Basic copolymers for the treatment of prion-related-disease
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
WO2003029276A2 (en) * 2001-10-03 2003-04-10 President And Fellows Of Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
EP1459065B1 (en) 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
WO2004064717A2 (en) 2003-01-21 2004-08-05 Yeda Research And Development Co. Ltd. Cop 1 for treatment of inflammatory bowel diseases
CN101287483B (zh) 2003-08-07 2012-02-29 希尔洛有限公司 用于加速伤口愈合的药物组合物和方法
CA2558655A1 (en) * 2004-03-01 2005-09-15 Kai W. Wucherpfennig Methods and compositions for treatment of autoimmune diseases
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US7560100B2 (en) 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
US7858337B2 (en) * 2007-03-08 2010-12-28 Novartis Ag Process for the manufacture of a composite material
US8399413B2 (en) 2009-08-20 2013-03-19 Yeda Research & Development Co., Ltd. Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
WO2012051106A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
CA2827275A1 (en) 2011-02-14 2012-09-20 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記
CN104098655B (zh) * 2013-04-09 2018-01-30 深圳翰宇药业股份有限公司 用于合成醋酸格拉替雷的质谱内标的多肽
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105218646B (zh) * 2014-06-24 2018-09-21 深圳翰宇药业股份有限公司 一种用于检测醋酸格拉替雷样本的uplc方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN107531750B (zh) * 2015-04-28 2021-03-16 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
EP3147667B1 (en) * 2015-09-24 2019-06-12 CHEMI S.p.A. Analysis of the molecular weight distribution of complex polypeptide mixtures
EP3600553A4 (en) 2017-03-26 2020-09-02 Mapi Pharma Ltd. GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers

Also Published As

Publication number Publication date
NO20011441D0 (no) 2001-03-21
IL209189A (en) 2017-11-30
AU757413B2 (en) 2003-02-20
EP1115743B1 (en) 2009-05-13
CA2794705C (en) 2017-07-18
CA2343929C (en) 2013-01-29
HUP0103889A2 (hu) 2002-03-28
JP2002525378A (ja) 2002-08-13
ATE431359T1 (de) 2009-05-15
IL209189A0 (en) 2011-01-31
HUP0103889A3 (en) 2004-03-01
NZ511020A (en) 2003-06-30
ES2408706T3 (es) 2013-06-21
IL142116A0 (en) 2002-03-10
DK2090583T3 (da) 2011-09-12
DK2239269T3 (da) 2013-04-29
IL209190A0 (en) 2011-01-31
CY1110490T1 (el) 2015-04-29
EP2090583A1 (en) 2009-08-19
EP1115743A4 (en) 2005-04-27
SI1115743T1 (sl) 2010-01-29
ZA200102269B (en) 2002-03-19
NO20100442L (no) 2001-05-25
PT2239269E (pt) 2013-04-09
EP2090583B1 (en) 2011-07-13
HU229719B1 (en) 2014-05-28
JP4629229B2 (ja) 2011-02-09
CY1113932T1 (el) 2016-07-27
DK1115743T3 (da) 2009-07-27
PT1115743E (pt) 2009-07-07
NO336685B1 (no) 2015-10-19
IL142116A (en) 2010-12-30
HU229289B1 (en) 2013-10-28
CA2343929A1 (en) 2000-04-06
EP2239269A1 (en) 2010-10-13
WO2000018794A1 (en) 2000-04-06
ES2327301T3 (es) 2009-10-27
HK1040521A1 (en) 2002-06-14
CY1112197T1 (el) 2015-12-09
NO20011441L (no) 2001-05-25
HU229720B1 (en) 2014-05-28
CA2794705A1 (en) 2000-04-06
JP2010271325A (ja) 2010-12-02
ATE516297T1 (de) 2011-07-15
EP1115743A1 (en) 2001-07-18
EP2239269B1 (en) 2013-01-16
PT2090583E (pt) 2011-09-14
NO329877B1 (no) 2011-01-17
HK1133021A1 (en) 2010-03-12
DE69940888D1 (de) 2009-06-25
JP4903886B2 (ja) 2012-03-28
AU6269599A (en) 2000-04-17
IL209190A (en) 2017-11-30
ES2369642T3 (es) 2011-12-02
DE09004306T1 (de) 2010-12-09

Similar Documents

Publication Publication Date Title
HK1149279A1 (en) Use of peptides derived from copolymer-1 as molecular weight markers
IL113812A0 (en) Copolymer-1, pharmaceutical compositions containing it and its use
EP0256092A4 (en) WEAKENED HERPESVIRUSES, HERPESVIRUSES THAT CONTAIN A FOREIGN DNA ENCODING AMINO ACID SEQUENCES, AND VACCINALS THAT CONTAIN THEM.
PT1091975E (pt) Nova ciclosporina com um perfil de actividade melhorado
EP0860461A3 (en) Polymerisation of cyclosiloxanes
FR2741806B1 (fr) Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
WO1997020933A3 (en) Mutational variants of mammalian ob gene proteins
DE50001905D1 (de) Herbizide mittel von nachauflauf-herbiziden zur bodenapplikation
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
DK0777468T3 (da) Medicinsk kontaktklæber
EP1080724A4 (en) COMPOSITIONS FOR REDUCING MTP ACTIVITY
DK0845034T3 (da) Peptid med pronociceptive egenskaber
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
ATE375390T1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
WO1997003205A3 (de) Neue dna-sequenzen und deren verwendung zur identifikation resistenzinduzierender agenzien in pflanzen
ATE303438T1 (de) Menschlicher cysteinyl leukotrien rezeptor 2 (cyslt2)
IT232230Y1 (it) Supporto per sci per trasporto o altro.

Legal Events

Date Code Title Description
PE Patent expired